达雷妥尤单抗治疗新诊断多发性骨髓瘤患者感染分析:MAIA与ALCYONE汇总分析
该汇总分析基于MAIA和ALCYONE两项III期研究,评估不适合移植的新诊断多发性骨髓瘤患者接受含达雷妥尤单抗方案(D-Rd或D-VMP)与标准方案(Rd或VMP)的感染发生率、时机及管理。结果显示D-Rd/D-VMP组3/4级感染发生率36.9%高于Rd/VMP组22.4%,5级感染3.0%对1.5%,但暴露调整后发生率总体相当;因感染停药约2%。
要点
- D-Rd/D-VMP组3/4级感染发生率36.9%,高于Rd/VMP组的22.4%。
- 两组5级感染发生率分别为3.0%和1.5%,暴露调整后总体相当。
- 3/4级感染最高发于治疗起始后前6个月内。
核心结论
- 含达雷妥尤单抗方案较标准方案提高3/4级和5级感染发生率,但暴露调整后总体相当且因感染停药率低。
研究设计与样本
- MAIA和ALCYONE两项III期研究的汇总分析,纳入不适合移植的新诊断多发性骨髓瘤患者,中位年龄72岁(范围40-93岁)。
主要发现
- D-Rd/D-VMP组3/4级感染发生率为36.9%,Rd/VMP组为22.4%。
- D-Rd/D-VMP组5级感染发生率为3.0%,Rd/VMP组为1.5%。
- 暴露调整后感染发生率两组总体相当。
- 任何级别感染导致研究治疗停药在各治疗组中约占2%。
- 3/4级感染最高发生率出现在治疗起始后前6个月内。
临床怎么用
- 临床医生应在整个治疗期间对感染保持警惕,并遵循当地指南和国际骨髓瘤工作组建议以降低感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care Rd (Revlimid [lenalidomide] and dexamethasone; D-Rd) or to VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP), respectively, vs Rd or VMP alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Patients with NDMM are highly susceptible to infection; therefore, gaining a greater understanding of infection incidence may help to mitigate future risk. We conducted a pooled analysis of infection incidence, timing, and management strategies from MAIA and ALCYONE. The median (range) age of the pooled population was 72 (40-93) years. Incidence was higher with D-Rd/D-VMP vs Rd/VMP for grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections; however, exposure-adjusted incidence rates were generally comparable between groups. Any-grade infections led to the discontinuation of study treatment in ∼2% of patients across treatment groups. Of the timing intervals explored, the highest incidence of grade 3/4 infection occurred within the first 6-month interval of study treatment initiation in both groups. Median time to the first onset of grade 3/4 infections (per Kaplan-Meier estimates) was 83.3 months and not estimable in the D-Rd/D-VMP and Rd/VMP groups, respectively. Although the rates of D-Rd/D-VMP treatment discontinuation due to infection remained low in MAIA and ALCYONE, clinicians should remain vigilant about infections throughout treatment and follow local guidelines and International Myeloma Working Group recommendations to minimize the risk of infection. These trials were registered at www.ClinicalTrials.gov as NCT02252172 (MAIA) and NCT02195479 (ALCYONE).
引用
- Bahlis N, Facon T, San-Miguel J, et al. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026. PMID: 42085642. doi:10.1182/bloodadvances.2025019323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。